CohBar Inc
OTC:CWBR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (1.4), the stock would be worth $0.4 (2% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.4 | $0.41 |
0%
|
| 3-Year Average | 1.4 | $0.4 |
-2%
|
| 5-Year Average | 1 | $0.3 |
-26%
|
| Industry Average | 15.1 | $4.42 |
+978%
|
| Country Average | 23.2 | $6.81 |
+1 561%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
CohBar Inc
OTC:CWBR
|
1.2m USD | 1.4 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 23.4 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 27.5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.1 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 31.2 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 13.5 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 139.4 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 20.5 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.4 |
| Median | 23.2 |
| 70th Percentile | 35.1 |
| Max | 3 178 983.5 |
Other Multiples
CohBar Inc
Glance View
CohBar, Inc. engages in the research and development of mitochondria-based therapeutics. The company is headquartered in Menlo Park, California and currently employs 9 full-time employees. The company went IPO on 2015-01-06. The firm focuses on developing therapeutics targeting chronic and age-related diseases. The company is advancing a pipeline of peptide analogs through varying stages of development, such as CB5138-3 for idiopathic pulmonary fibrosis (IPF); CB4211 for the treatment of non-alcoholic steatohepatitis (NASH) and obesity; and several preclinical and discovery-stage programs. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing, and optimizing analogs of these natural mitochondrial derived peptides (MDPs), as well as developing and conducting screens to identify and characterize the activities of these peptides are referred to its Mito+ platform. The company is using its Mito+ platform to identify and develop modified versions of natural peptides called analogs, to treat a range of serious conditions, with a focus on chronic diseases involving inflammation and fibrosis.
